IP Library › Granted Patent US 12,318,408
Granted Patent B2
US 12,318,408 · App. 18/101,727 · Granted Jun 3, 2025

Methods of manufacture of therapeutic products comprising vitalized placental dispersions

Inventors: Samson Tom (Baltimore, MD); Alla Danilkovitch (Columbia, MD); Dana Yoo (Falls Church, VA); Timothy Jansen (Baltimore, MD); Jin-Qiang Kuang (Woodstock, MD); Jennifer Michelle Marconi (Glen Burnie, MD)
Assignee: OSIRIS THERAPEUTICS, INC.
A61K35/28A01N1/125A61K35/50A61K38/1825A61K38/1841A61K38/39A61K38/57C12N5/0605C12N2500/02C12N2501/115C12N2502/025
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,318,408
App. No.
18/101,727
Granted
Jun 3, 2025
Kind
B2
Abstract

This invention provides a fluid therapeutic placental product comprising placental cells and a placental dispersion comprising placental factors. The placental cells and the placental dispersion are derived from placental tissue. A placental tissue can optionally be an amnion, chorion, or a trophoblast-depleted chorion. The placental product of the present invention is useful in treating a patient with a tissue injury (e.g. wound or burn) by applying the placental product to the injury. Similar application is useful with ligament and tendon repair and for engraftment procedures such as bone engraftment.

Claims (23)

1. A method of treating a tissue injury in a patient, the method comprising:

a) obtaining a placental dispersion comprising:

(i) disrupted chorionic tissue; and

(ii) placental cells from chorionic tissue, wherein the placental cells are not cultured or expanded ex vivo, and

wherein the chorionic tissue is substantially free of trophoblasts; and

b) applying the placental dispersion to the tissue injury.

2. The method of claim 1 , wherein the disrupted chorionic tissue is derived from the same chorionic tissue as the placental cells.

3. The method of claim 2 , further comprising enzymatically digesting the chorionic tissue before disrupting the chorionic tissue to provide the disrupted chorionic tissue.

4. The method of claim 1 , wherein the disrupted chorionic tissue is derived from a chorionic tissue that is different from the chorionic tissue from which the placental cells are derived.

5. The method of claim 1 , wherein the placental cells comprise one or more of mesenchymal stem cells, embryonic stem cells, placenta-derived mesenchymal progenitor cells, placental mesenchymal stem cells, fibroblasts, epithelial cells, placental mesenchymal cells, stromal cells, macrophages, or combinations thereof.

6. The method of claim 1 , wherein the placental cells are present at a concentration of at least about 20,000 per ml of the placental dispersion.

7. The method of claim 1 , wherein the placental dispersion further comprises one or more placental-derived factors.

8. The method of claim 7 , wherein the one or more placental-derived factors comprises one or more of extracellular matrix proteins, angiogenic factors, chemokines, cytokines, growth factors, matrix metalloproteinases, or combinations thereof.

9. The method of claim 7 , wherein the one or more placental-derived factors are produced by the placental dispersion up to 14 days after application to the tissue injury.

10. The method of claim 1 , wherein the placental dispersion is thawed after cryopreservation of the placental dispersion.

11. The method of claim 1 , wherein the placental dispersion is rehydrated after lyophilization of the placental dispersion.

12. The method of claim 1 , wherein the placental dispersion is applied to about 1 cm 2 to about 100 cm 2 of the tissue injury.

13. The method of claim 1 , wherein the placental dispersion has a viscosity of 1,000 cps to 15,000 cps or 20,000 cps to 200,000 cps.

14. The method of claim 1 , wherein the placental dispersion does not comprise ex vivo expanded or cultured cells.

15. The method of claim 1 , wherein the placental dispersion is formulated with one or more thickening agents, antibiotics, emollients, keratolytic agents, humectants, anti-oxidants, preservatives, electrolyte solutions, albumin, or combinations thereof.

16. The method of claim 1 , wherein the placental dispersion is comprised in a bandage or wound dressing.

17. The method of claim 1 , wherein the placental dispersion is comprised in an implant.

18. The method of claim 1 , wherein the tissue injury is a burn, wound, ulceration, laceration, ablations, or surgical incision.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 26, 2023
From: TOM, SAMSON; DANILKOVITCH, ALLA; YOO, DANA; JANSEN, TIMOTHY; KUANG, JIN-QIANG; MARCONI, JENNIFER MICHELLE
To: OSIRIS THERAPEUTICS, INC.
Reel/Frame 062497/0189 →
Continuity (8)
Continuation 16841359 · Apr 6, 2020
Continuation 15949808 · Apr 10, 2018
Continuation 14070040 · Nov 1, 2013
Continuation 13030595 · Feb 18, 2011
Provisional Application 61369562 · Jul 30, 2010
Provisional Application 61338489 · Feb 18, 2010
Provisional Application 61338464 · Feb 18, 2010
Related Publication 20240050482A1 · Feb 15, 2024
References Cited (332)
US 5891617A · Watson et al. · 1999 [cited by applicant]
US 6152142A · Tseng · 2000 [cited by applicant]
US 6326019B1 · Tseng · 2001 [cited by applicant]
US 7928280B2 · Hariri et al. · 2011 [cited by applicant]
US 8071135B2 · Liu et al. · 2011 [cited by applicant]
US 8460715B2 · Daniel · 2013 [cited by applicant]
US 8932641B2 · Nikaido et al. · 2015 [cited by applicant]
US 9956248B2 · Tom et al. · 2018 [cited by applicant]
US 10272116B2 · Tom et al. · 2019 [cited by applicant]
US 10576104B2 · Tom et al. · 2020 [cited by applicant]
US 11510947B2 · Tom et al. · 2022 [cited by applicant]
US 20020039788A1 · Isseroff et al. · 2002 [cited by applicant]
US 20030032179A1 · Hariri · 2003 [cited by applicant]
US 20030187515A1 · Hariri et al. · 2003 [cited by applicant]
US 20030235563A1 · Strom et al. · 2003 [cited by applicant]
US 20040048796A1 · Harari et al. · 2004 [cited by applicant]
US 20050176139A1 · Chen · 2005 [cited by examiner]
US 20060003927A1 · Champion et al. · 2006 [cited by applicant]
US 20060111778A1 · Michalow · 2006 [cited by applicant]
US 20060182724A1 · Riordan · 2006 [cited by applicant]
US 20060023376A1 · Messina et al. · 2006 [cited by applicant]
US 20060228339A1 · Wang · 2006 [cited by applicant]
US 20070015278A1 · Li et al. · 2007 [cited by applicant]
US 20070041954A1 · Ichim · 2007 [cited by applicant]
US 20070071740A1 · Tseng et al. · 2007 [cited by applicant]
US 20070116684A1 · Atala et al. · 2007 [cited by applicant]
US 20070134210A1 · Heidaran · 2007 [cited by applicant]
US 20070134261A1 · Hancock et al. · 2007 [cited by applicant]
US 20070148214A1 · Cullen · 2007 [cited by applicant]
US 20070178159A1 · Chen et al. · 2007 [cited by applicant]
US 20070231297A1 · Smith et al. · 2007 [cited by applicant]
US 20070275362A1 · Edinger et al. · 2007 [cited by applicant]
US 20080044848A1 · Heidaran · 2008 [cited by applicant]
US 20080046095A1 · Daniel · 2008 [cited by applicant]
US 20080064098A1 · Allickson et al. · 2008 [cited by applicant]
US 20080069895A1 · Liu et al. · 2008 [cited by applicant]
US 20080131522A1 · Liu et al. · 2008 [cited by applicant]
US 20080138396A1 · Low et al. · 2008 [cited by applicant]
US 20080145344A1 · Deshpande et al. · 2008 [cited by applicant]
US 20080152629A1 · Edinger et al. · 2008 [cited by applicant]
US 20080175824A1 · Heidaran et al. · 2008 [cited by applicant]
US 20080181935A1 · Bhatia · 2008 [cited by applicant]
US 20080181967A1 · Liu et al. · 2008 [cited by applicant]
US 20080193554A1 · Dua et al. · 2008 [cited by applicant]
US 20080213228A1 · Edinger et al. · 2008 [cited by applicant]
US 20080213332A1 · Slavin et al. · 2008 [cited by applicant]
US 20080226595A1 · Edinger et al. · 2008 [cited by applicant]
US 20080299087A1 · Tseng et al. · 2008 [cited by applicant]
US 20090104164A1 · Zhang et al. · 2009 [cited by applicant]
US 20090169597A1 · Brown et al. · 2009 [cited by applicant]
US 20090252710A1 · Zhang et al. · 2009 [cited by applicant]
US 20100047351A1 · Zeitlin et al. · 2010 [cited by applicant]
US 20100098743A1 · Nikaido et al. · 2010 [cited by applicant]
US 20100119496A1 · Wilkison et al. · 2010 [cited by applicant]
US 20100260847A1 · Hariri · 2010 [cited by applicant]
US 20110206776A1 · Tom et al. · 2011 [cited by applicant]
US 20110212063A1 · Tom et al. · 2011 [cited by applicant]
US 20110212064A1 · Jansen et al. · 2011 [cited by applicant]
US 20110212065A1 · Jansen et al. · 2011 [cited by applicant]
US 20110212158A1 · Tom et al. · 2011 [cited by applicant]
US 20110251566A1 · Zimnitsky et al. · 2011 [cited by applicant]
US 20110256202A1 · Tom et al. · 2011 [cited by applicant]
US 20120095455A1 · Rodmond et al. · 2012 [cited by applicant]
US 20140037598A1 · Jansen et al. · 2014 [cited by applicant]
US 20140127177A1 · Tom et al. · 2014 [cited by applicant]
US 20140127317A1 · Jansen et al. · 2014 [cited by applicant]
US 20140140966A1 · Tom et al. · 2014 [cited by applicant]
US 20140160447A1 · Kobayashi et al. · 2014 [cited by applicant]
US 20140294777A1 · Tom et al. · 2014 [cited by applicant]
US 20140301986A1 · Tom et al. · 2014 [cited by applicant]
US 20150010506A1 · Jansen et al. · 2015 [cited by applicant]
US 20150010609A1 · Tom et al. · 2015 [cited by applicant]
US 20150010610A1 · Tom et al. · 2015 [cited by applicant]
US 20180360886A1 · Tom et al. · 2018 [cited by applicant]
US 20200000853A1 · Tom et al. · 2020 [cited by applicant]
AU 2014393402 · 2016 [cited by applicant]
AU 2014393403 · 2016 [cited by applicant]
AU 2014393404 · 2016 [cited by applicant]
CA 2790322 · 2011 [cited by applicant]
CA 2790325 · 2011 [cited by applicant]
CA 2790333 · 2011 [cited by applicant]
CA 2790336 · 2011 [cited by applicant]
CA 2790340 · 2011 [cited by applicant]
CA 2790436 · 2011 [cited by applicant]
CA 2948129 · 2015 [cited by applicant]
CA 2948126 · 2016 [cited by applicant]
CA 2948133 · 2016 [cited by applicant]
EP 2536825 · 2011 [cited by applicant]
EP 2536826 · 2011 [cited by applicant]
EP 2702871 · 2014 [cited by applicant]
EP 3139934 · 2017 [cited by applicant]
EP 3139935 · 2017 [cited by applicant]
EP 3139936 · 2017 [cited by applicant]
EP 2536823 · 2017 [cited by applicant]
EP 2536417 · 2018 [cited by applicant]
EP 2536827 · 2018 [cited by applicant]
EP 2536824 · 2018 [cited by applicant]
EP 3345998 · 2018 [cited by applicant]
EP 3351622 · 2018 [cited by applicant]
EP 3351624 · 2018 [cited by applicant]
EP 3351625 · 2018 [cited by applicant]
JP 2016566997 · 2016 [cited by applicant]
JP 2016567041 · 2016 [cited by applicant]
JP 2016566889 · 2017 [cited by applicant]
JP 2017514876 · 2017 [cited by applicant]
JP 2017514879 · 2017 [cited by applicant]
KR 1020167034113 · 2016 [cited by applicant]
KR 1020167034174 · 2016 [cited by applicant]
KR 1020167034202 · 2016 [cited by applicant]
KR 20160147058 · 2016 [cited by applicant]
KR 20170002572 · 2017 [cited by applicant]
SG 11201609253P · 2016 [cited by applicant]
SG 11201609254Y · 2016 [cited by applicant]
SG 11201609255X · 2016 [cited by applicant]
WO WO1989007425 · 1989 [cited by applicant]
WO WO1998037903 · 1998 [cited by applicant]
WO WO2005001076 · 2005 [cited by applicant]
WO WO2005007835 · 2005 [cited by applicant]
WO WO2005021014 · 2005 [cited by applicant]
WO WO2006016828 · 2006 [cited by applicant]
WO WO2006071794 · 2006 [cited by applicant]
WO WO2006094247 · 2006 [cited by applicant]
WO WO2007009062 · 2007 [cited by applicant]
WO WO2007023750 · 2007 [cited by applicant]
WO WO2007079183 · 2007 [cited by applicant]
WO WO2007079184 · 2007 [cited by applicant]
WO WO2008040557 · 2008 [cited by applicant]
WO WO2008060377A2 · 2008 [cited by examiner]
WO WO2008146991 · 2008 [cited by applicant]
WO WO2008151846 · 2008 [cited by applicant]
WO WO2008156659 · 2008 [cited by applicant]
WO WO2009044408 · 2009 [cited by applicant]
WO WO2009120996 · 2009 [cited by applicant]
WO WO2009132186 · 2009 [cited by applicant]
WO WO2011074208 · 2011 [cited by applicant]
WO WO2011103446 · 2011 [cited by applicant]
WO WO2011103451 · 2011 [cited by applicant]
WO WO2011103455 · 2011 [cited by applicant]
WO WO2011103462 · 2011 [cited by applicant]
WO WO2011103470 · 2011 [cited by applicant]
WO WO2011103472 · 2011 [cited by applicant]
WO WO2015171142 · 2015 [cited by applicant]
WO WO2015171143 · 2015 [cited by applicant]
WO WO2015171144 · 2015 [cited by applicant]
Mihu, Carmen Mihaela; et al; “Isolation and characterization of stem cells from the placenta and the umbilical cord” Romanian Journal of Morphology and Embryology, 49, 441-446, 2008 (Year: 2008). [cited by examiner]
“Grafix® Cellular Repair Matrix For the Treatment of Bums”, Osiris Therapeutics, Inc., Mar. 1, 2012. [cited by applicant]
Adds et al., “Amniotic membrane grafts, “fresh” or frozen? A clinical and in vitro comparison,” Br. J. Ophthalmol., 85 (8):905-907 (2001). [cited by applicant]
Aggarwal et al, “Human mesenchymal stem cells modulate allogeneic immune cell responses,” Blood, 105:1815-1822 (2005). [cited by applicant]
Akle et al., “Immunogenicity of human amniotic epithelial cells after transplantation into volunteers,” Lancet, 2 (8254):1003-1005 (1981). [cited by applicant]
Allen et al., “Periosteum: biology, regulation, and response to osteoporosis therapies,” Bone, 35:1003-1012 (2004). [cited by applicant]
Allori et al., “Biological Basis of Bone Formation, Remodeling, and Repair—Part I: Biochemical Signaling Molecules,” Tissue Engineering: Part B, 14(3):259-273 (2008). [cited by applicant]
Allori et al., “Biological basis of bone formation, remodeling, and repair—part II: extracellular matrix,” Tissue Eng. Part B Rev., 14(3):275-283 (2008). [cited by applicant]
Asplin et al., “Differential regulation of the fibroblast growth factor (FGF) family by alpha(2)-macroglobulin: evidence for selective modulation of FGF-2-induced angiogenesis,” Blood, 97(11 ):3450-3457 (2001). [cited by applicant]
Atanassov, W., J. Mazgalova, and R. Todorov, Use of amniotic membranes as biological dressings in contemporary treatment of bums. Ann Med Bum Club, 1994. [cited by applicant]
Babalola, et al., “Aggregation of dispersed human cytotrophoblastic cells: Lessons relevant to the morphogenesis of the placenta”, Developmental Biology, Academic Press, Amsterdam, NL, vol. 137, No. 1, Jan. 1, 1990 (Jan… [cited by applicant]
Bagot et al., “Reconstructed human epidermis: absence of Langerhans cells and failure to stimulate allogeneic lymphocytes in vitro,” Clin. Exp. Immunol., 71(1):138-143 (1988). [cited by applicant]
Bailo et al., “Engraftment potential of human amnion and chorion cells derived from term placenta,” Transplantation, 78 (10):1439-1448 (2004). [cited by applicant]
Baker et al., “Metalloproteinase inhibitors: biological actions and therapeutic opportunities,” J. Cell Sei., 115(Pt 19):3719-3727 (2002). [cited by applicant]
Bannasch et al., “Treatment of chronic wounds with cultured autologous keratinocytes as suspension in fibrin glue,” Zentralbl Chir., 125 Suppl 1 :79-81 (2000) (Abstract). [cited by applicant]
Bergeson et al., “Fetal membrane collagens: Identification of two new collagen alpha chains,” Proc. Natl. Acad. Sci. USA, 73(8):2579-2583 (1976). [cited by applicant]
Bertolami et al., “The Role of Proteoglycans in Hard and Soft Tissue Repair,” Crit. Rev. Oral Biol. Med., 5 (3&4):311-337 (1994). [cited by applicant]
Bielby et al., “The role of mesenchymal stem cells in maintenance and repair of bone,” Injury, Int. J. Care Injured, 38S1: S26-S32 (2007). [cited by applicant]
Borth et al., “Alpha 2-macroglobulin, a multifunctional binding protein with targeting characteristics,” FASEB J., 6 (15):3345-3353 (1992). [cited by applicant]
Branski, L.K., et al., Amnion in the treatment of pediatric partial-thickness facial bums. Burns, 2008. 34(3): p. 393-9. [cited by applicant]
Bravo et al., Effect of Storage on Preservation Methods on Viability in Transplantable Human Skin Allografts. Burns. 2000; 26:367-78. [cited by applicant]
Bruder et al., “Bone Regeneration by Implantation of Purified, Culture-Expanded Human Mesenchymal Stern Cells,” J. Ortho. Res., 16:155-162 (1998). [cited by applicant]
Bruder et al., “Mesenchymal Stern Cells in Osteobiology and Applied Bone Regeneration,” Clin. Ortho. Rel. Res., 355S:S247-S256 (1998). [cited by applicant]
Bryant-Greenwood, G.D., The extracellular matrix of the human fetal membranes: structure and function. Placenta, 1998. 19(1): p. 1-11. [cited by applicant]
Carter et al., “Immunolocalization of collagen types I and III, tenascin, and fibronectin in intramembranous bone,” J. Histochem. Cytochem., 39(5):599-606 (1991). [cited by applicant]
Chang et al., “Rotator cuff repair with periosteum for enhancing tendon-bone healing: a biomechanical and histological study in rabbits,” Knee Surg. Sports Traumatol. Arthrose., 17(12):1447-1453 (2009). [cited by applicant]
Chen et al., “Enveloping of periosteum on the hamstring tendon graft in anterior cruciate ligament reconstruction,” Arthroscopy, 18(5):27E (2002). [cited by applicant]
Chen et al., “Enveloping the tendon graft with periosteum to enhance tendon-bone healing in a bone tunnel: A biomechanical and histologic study in rabbits,” Arthroscopy, 19(3):290-296 (2003). [cited by applicant]
Chen et al., “Hypoxia and transforming growth factor-beta 1 act independently to increase extracellular matrix production by placental fibroblasts,” J. Clin. Endocrinol. Metab., 90(2):1083-1090 (2005). [cited by applicant]
Chen, L., et al., Paracrine factors of mesenchymal stem cells recruit macrophages and endothelial lineage cells and enhance wound healing. PLoS One, 2008. 3(4): p. e1886. [cited by applicant]
Choi et al: “Full-Thickness Skin Wound Healing Using Human Placenta-Derived Extracellular Matrix Containing Bioactive Molecules”, Tissue Engineering Part A, (2013); 19(3&4):329-339. [cited by applicant]
Clarke, “Normal Bane Anatomy and Physiology,” Clin. J. Am. Soc. Nephrol., 3:S131-S139 {2008). [cited by applicant]
Database WPI Week 200522, Thomson Scientific. London. GB; AN 2005-214449; XP-002774389. [cited by applicant]
Davis, J.W., Skin transplantation with a review of 550 cases at the Johns Hopkins Hospital. Johns Hopkins Med J, 1910. 15. [cited by applicant]
De Rotth, “Plastic repair of conjunctival defects with fetal membranes,” Arch. Ophthalmol., 23:522-525 (1940). [cited by applicant]
Devescovi et al., “Growth factors in bone repair,” Chir. Organi. Mov., 92:161-168 (2008). [cited by applicant]
Dickinson et al., “Monoclonal anti-TNF-alpha suppresses graft vs hast disease reactions in an in vitro human skin model,” Cytokine, 6(2):141-146 (1994). [cited by applicant]
Dioguardi, D., E. Brienza, and M. De Robertis, Skin Substitutes in bum treatment—our experience. Ann Med Bum Club, 1990. [cited by applicant]
Dua, Harminder S; Azuara-Blanco, Augusto; “Amniotic membrane transplantation” British Journal of Ophthalmology, 83, 748-752, (1999). [cited by applicant]
Dwek, “The periosteum: what is it, where is it, and what mimics it in its absence?” Skeletal Radial., 39:319-323 {2010). [cited by applicant]
E. Dimitriadis: “Cytokines, Chemokines and Growth Factors in Endometrium Related to Implantation”, Human Reproduction Update, Val. 11, No. 6, Aug. 25, 2005 (Aug. 25, 2005), pp. 613-630, ISSN: 1355-4786, DOI: 10.10931 hu… [cited by applicant]
Eldad, A; et al; “Amniotic membranes as a biological dressing” South African Medical Journal, 51, 272-275,(1977). [cited by applicant]
Extend Search Report & Opinion issued in European Application No. 11745341, dated Apr. 1, 2014. [cited by applicant]
Extend Search Report & Opinion issued in European Application No. 11745343, dated Apr. 1, 2014. [cited by applicant]
Extend Search Report & Opinion issued in European Application No. 11745347, dated Apr. 24, 2014. [cited by applicant]
Extend Search Report & Opinion issued in European Application No. 11745353, dated Apr. 24, 2014. [cited by applicant]
Extend Search Report & Opinion issued in European Application No. 11745360, dated Feb. 18, 2011. [cited by applicant]
Extend Search Report & Opinion issued in European Application No. 11745361, dated May 9, 2014. [cited by applicant]
Extend Search Report & Opinion issued in European Application No. 14891208, dated Oct. 13, 2017. [cited by applicant]
Extend Search Report & Opinion issued in European Application No. 14891336, dated Oct. 13, 2017. [cited by applicant]
Extend Search Report & Opinion issued in European Application No. 14891554 dated Oct. 17, 2017. [cited by applicant]
Extend Search Report & Opinion issued in European Application No. 17205385, dated May 4, 2018. [cited by applicant]
Extend Search Report & Opinion issued in European Application No. 17207766, dated May 24, 2018. [cited by applicant]
Extend Search Report & Opinion issued in European Application No. 17211013, dated Apr. 24, 2018. [cited by applicant]
Extend Search Report & Opinion issued in European Application No. 17211018, dated May 25, 2018. [cited by applicant]
Fan et al., “Synovium-Derived Mesenchymal Stern Cells: A New Cell Source for Musculoskeletal Regeneration,” Tissue Engineering: Part B, 15{1 ):75-86 (2009). [cited by applicant]
Fortunato et al., “I. Organ Culture of Amniochorionic Membrane In Vitro,” Am. J. Reprod. Immunol., 32:184-187 (1994). [cited by applicant]
Fortunato et al., “Inflammatory cytokine (interleukins 1, 6 and 8 and tumor necrosis factor-alpha) release from cultured human fetal membranes in response to endotoxic lipopolysaccharide mirrors amniotic fluid concentra… [cited by applicant]
Gajiwala, K. and A. Lobo Gajiwala, Use of banked tissue in plastic surgery. Cell Tissue Bank, 2003. 4(2-4): p. 141-6. [cited by applicant]
Gajiwala, K. and A.L. Gajiwala, Evaluation of lyophilised, gamma-irradiated amnion as a biological dressing. Cell Tissue Bank, 2004. 5(2): p. 73-80. [cited by applicant]
Galiano et al., “Interaction between the insulin-like growth factor family and the integrin receptor family in tissue repair processes. Evidence in a rabbit ear dermal ulcer model,” J. Clin. Invest., 98(11 ):2462-2468 (… [cited by applicant]
Ganatra, M.A. and K.M. Durrani, Method of obtaining and preparation of fresh human amniotic membrane for clinical use. J Pak Med Assoc, 1996. 46(6): p. 126-8. [cited by applicant]
Genbacev, Olga; et al; “Serum-free derivation of human embryonic stem cell lines on human placental fibroblast feeders” Fertility and Sterility, 83, 1517-1529, (2005). [cited by applicant]
Goldman, “Growth factors and chronic wound healing: past, present, and future,” Adv. Skin Wound Care, 17:24-35 (2004). [cited by applicant]
Greenhalgh et al., “PDGF and FGF stimulate wound healing in the genetically diabetic mouse,” Am. J. Pathol., 136 (6):1235-1246 (1990). [cited by applicant]
Haberal, M., et al., The use of silver nitrate-incorporated amniotic membrane as a temporary dressing. Burns Incl Therm Inj, 1987. 13(2): p. 159-63. [cited by applicant]
Hadjiiski, 0. and N. Anatassov, Amniotic membranes for temporary bum coverage. Ann Bums Fire Disasters, 1996. [cited by applicant]
Hieber, A.D., et al., Detection of elastin in the human fetal membranes: proposed molecular basis for elasticity. Placenta, 1997. 18(4): p. 301-12. [cited by applicant]
Hacking, A.M. and N.S. Gibran, Mesenchymal stem cells: paracrine signaling and differentiation during cutaneous wound repair. Exp Cell Res. 316(14): p. 2213-9. [cited by applicant]
Hong et al., “The effect of various concentrations of human recombinant epidermal growth factor on split-thickness skin wounds,” Int. Wound J., 3:123-130 (2006). [cited by applicant]
Huang et al., “Human transforming growth factor beta.alpha 2-macroglobulin complex is a latent form of transforming growth factor beta,” J. Biol. Chem., 263(3):1535-1541 (1988). [cited by applicant]
Hutmacher et al., “Periosteal Cells in Bane Tissue Engineering,” Tissue Engineering, 9(Supp 1 ):S-45-8-64 (2003). [cited by applicant]
Ilancheran et al., “Human fetal membranes: a source of stem cells for tissue regeneration and repair?” Placenta, 30:2-10 (2009). [cited by applicant]
International Search Report & Written Opinon issued in PCT/US2011/025459, dated May 3, 2011. [cited by applicant]
International Search Report & Written Opinon issued in PCT/US2011/025465, dated Apr. 14, 2011. [cited by applicant]
International Search Report & Written Opinon issued in PCT/US2011/025469, dated Apr. 27, 2011. [cited by applicant]
International Search Report & Written Opinon issued in PCT/US2011/025478, dated May 25, 2011. [cited by applicant]
International Search Report & Written Opinon issued in PCT/US2011/025490, dated Apr. 13, 2011. [cited by applicant]
International Search Report & Written Opinon issued in PCT/US2011/025493, dated May 4, 2011. [cited by applicant]
International Search Report & Written Opinon issued in PCT/US2011/025498, dated May 4, 2011. [cited by applicant]
International Search Report & Written Opinon issued in PCT/US2014/037201, dated Sep. 29, 2014. [cited by applicant]
International Search Report & Written Opinon issued in PCT/US2014/037204, dated Sep. 29, 2014. [cited by applicant]
International Search Report & Written Opinon issued in PCT/US2014/037208, dated Sep. 29, 2014. [cited by applicant]
Izumi et al., “Mortality of first-time amputees in diabetics: a 10-year observation,” Diabetes Res. Clin. Pract., 83:126-131 (2009). [cited by applicant]
Jafari, et al., “Human amniotic mesenchymal stem cells promote/suppress cancer; two sides of the same coin”, [cited by applicant]
Jordan et al., “Optimal analysis of composite cytokine responses during alloreactivity,” J. Immunol. Methods, 260:1-14 (2002). [cited by applicant]
Kasi, N., K.M. Durrani, and M.A. Siddiqui, Human amniotic membrane as a versatile biological dressing—a preliminary report. J Pak Med Assoc, 1987. 37(11 ): p. 290-2. [cited by applicant]
Kawai et al., “Effects of adiponectin on growth and differentiation of human keratinocytes-implication of impaired wound healing in diabetes,” Biochem. Biophys. Res. Commun., 374:269-273 (2008). [cited by applicant]
Keene et al., “Human bone contains type III collagen, type VI collagen, and fibrillin: type III collagen is present on specific fibers that may mediate attachment of tendons, ligaments, and periosteum to calcified bone … [cited by applicant]
Kesting et al., “The role of allogenic amniotic membrane in burn treatment,” J. Burn Care Res., 29:907-916 (2008). [cited by applicant]
“Ketheesan et al., The effect of cryopreservation on the immunogenicity of allogeneic cardiac valves. Gryobiology. 1996; 33:41-53.” [cited by applicant]
Kim et al., “Coexpression of myofibroblast and macrophage markers: novel evidence for an in vivo plasticity of chorioamniotic mesodermal cells of the human placenta,” Lab Invest., 88:365-374 (2008). [cited by applicant]
Komarcevic et al., “New views on the physiology of wound healing,” Med. Pregl., 53(9-10):479-483 (Abstract) (2000). [cited by applicant]
Komatsu et al., “The Control of Fracture Healing and Its Therapeutic Targeting: Improving Upon Nature,” J. Cell. Biochem., 109:302-311 (2010). [cited by applicant]
“Koob, T.J. et al: ““Biological properties of dehydrated human amnion/chorion composite graft: implications for chronic wound healing””. International Wound Journal. (2013); 10(5): 493-500.” [cited by applicant]
Kruse F. E. et Al: Cryopreserved Human Amniotic Membrane For Ocular Surface Reconstruction, Graefe's Archive For Clinical And Experimental Ophthalmology, Springer Verlag, DE, Val. 238, No. 1, Jan. 1, 2000 (Jan. 1, 2000)… [cited by applicant]
Kubo et al., Immunogenicity of 1-3,7, Human Amniotic Membrane in Experimental 19,15 Xenotransplantation, Invest Ophthalmol Visual Sei. 1991; 1539. [cited by applicant]
Kubo et al,, “Immunogenicity of human amniotic membrane in experimental xenotransplantation” Invest Ophthalmol Vis Sci. Jun. 2001;42(7):1539-46. [cited by applicant]
Kwan et al., “Scar and contracture: biological principles,” Hand Clin., 25:511-528 (2009). [cited by applicant]
Ley-Chavez, E., et al., Application of biological dressings from radiosterilized amnios with cobalt 60 and serologic studies on the handling of burns in pediatric patients. Ann Transplant, 2003. 8(4): p. 46-9. [cited by applicant]
Li, H; et al; “Hypoxia-induced Increase in Soluble Flt-1 Production Correlates with Enhanced Oxidative Stress in Trophoblast Cells from the Human Placenta” Placenta, 26, 210-217,(2005). [cited by applicant]
Lin, S.D., et al., Amnion overlay meshed skin auto graft. Burns Incl Therm Inj, 1985. 11(5): p. 374-8. [cited by applicant]
Liu et al., “Increased matrix metalloproteinase-9 predicts poor wound healing in diabetic foot ulcers,” Diabetes Care, 32:117-119 (2009). [cited by applicant]
Livingston et al., “Mesenchymal stem cells combined with biphasic calcium phosphate ceramics promote bone regeneration,” J. Mat. Sci.: Mat. Med., 14:211-218 (2003). [cited by applicant]
Lomas et al., “Application of a high-level peracetic acid disinfection protocol to re-process antibiotic disinfected skin allografts,” Cell Tissue Bank, 5:23-36 (2004). [cited by applicant]
Lorusso, R., V. Geraci, and M. Masellis, The treatment of superficial burns with biological and synthetic material: frozen amnion and biobrane. Ann Med Burn Club, 1989. [cited by applicant]
Lue et al., “Engagement of CD14 on human monocytes terminates T cell proliferation by delivering a negative signal to T cells,” J. Immunol., 147(4):1134-1138 (1991). [cited by applicant]
Maddalena Soncini et al: “Isolation and characterization of mesenchymal cells from human fetal membranes”, Journal of Tissue Engineering and Regenerative Medicine, (2007) 1 :296-305. [cited by applicant]
Magatti et al., “Human amnion mesenchyme harbors cells with allogeneic T-cell suppression and stimulation capabilities,” Stern Cells, 26:182-192 (2008). [cited by applicant]
Magliacani, G., The surgical treatment of burns: skin substitutes. Ann Med Burn Club, 1990. [cited by applicant]
Majors et al., “Characterization of human bone marrow stromal cells with respect to osteoblastic differentiation,” J. Orthop. Res., 15:546-557 (1997). [cited by applicant]
Malak et al., “Confocal immunofluorescence localization of collagen types I, III, IV, V and VI and their ultrastructural organization in term human fetal membranes,” Placenta, 14(4):385-406 (1993). [cited by applicant]
Malhotra et al., Human amniotic membrane transplantation: Different modalities of its use in ophthalmology. World J. Transplant, Jun. 24, 2014; 4(2); 111-121. [cited by applicant]
Malizos et al., “The healing potential of the periosteum Molecular aspects,” Injury, Int. J. Care Injured, 36S-S 13-S 19 (2005). [cited by applicant]
Mathew, S., et al., “Characterization of the interaction between α2macroglobulin and fibroblast growth factor-2: the role of hydrophobic interactions”, Dept. of Pathology, pp. 123-129. [cited by applicant]
Meinert et al., “Proteoglycans and hyaluronan in human fetal membranes,” Am. J. Obstet. Gynecol., 184(4):679-685 (2001). [cited by applicant]
Meller, D. et al., Amniotic Membrane Transplantation in the Human Eye. Dtsch Arztebl Int. 2011; 108(14) :243-8. [cited by applicant]
Midura et al., “Parathyroid Hormone Rapidly Stimulates hyaluronan Synthesis by Periosteal Osteoblasts in the Tibial Diaphysis of the Growing Rat,” J. Biol. Chem., 278(51):51462-51468 (2003). [cited by applicant]
Mwaura et al., “The impact of differential expression of extracellular matrix metalloproteinase inducer, matrix metalloproteinase-2, tissue inhibitor of matrix metalloproteinase-2 and PDGF-AA on the chronicity of venous… [cited by applicant]
Nauth et al., “Bone morphogenetic proteins in open fractures: past, present, and future,” Injury, Int. J. Care Injured, 40: S3, S27-S31 (2009). [cited by applicant]
Nedelec et al., “The effect of interferon alpha 2b on the expression of cytoskeletal proteins in an in vitro model of wound contraction,” J. Lab. Clin. Med., 126:474-484 (1995). [cited by applicant]
Niknejad et al. “Properties of the Amniotic Membrane for Potential Use in Tissue Engineering” European Cells and Materials, (2008)15: 88-99. [cited by applicant]
Occleston et al., “Prevention and reduction of scarring in the skin by Transforming Growth Factor beta 3 (TGFbeta3): from laboratory discovery to clinical pharmaceutical,” J. Biomater. Sci. Polym. Ed., 19:1047-1063 (200… [cited by applicant]
O'Driscoll et al., “The chondrogenic potential of periosteum decreases with age,” J. Ortho. Res., 19:95-103 (2001). [cited by applicant]
Ohashi et al., “Advanced glycation end products enhance monocyte activation during human mixed lymphocyte reaction,” Clin. Immunol., 134:345-353 (2009). [cited by applicant]
Onishi et al., “Distinct and overlapping patterns of localization of bone morphogenetic protein (BMP) family members and a BMP type II receptor during fracture healing in rats,” Bone, 22(6):605-612 (1998). [cited by applicant]
“Ornella et al., Concise review: isolation and characterization of cells from human term placenta: outcome of the first international Workshop on Placenta Derived Stern Cells. Stem Cells. 2008; 26(2):300-11.” [cited by applicant]
Page et al., “Critiquing clinical research of new technologies for diabetic foot wound management,” J. Foot Ankle Surg., 41(4):251-259 (2002). [cited by applicant]
Papadaki, M., “Cellular/tissue engineering—Promises and Challenges in Tissue Engineering”, [cited by applicant]
Paquet-Fifield et al., “A role for pericytes as microenvironmental regulators of human skin tissue regeneration,” J. Clin. Invest, 119:2795-2806 (2009). [cited by applicant]
Paradowska et al., “Constitutive and induced cytokine production by human placenta and amniotic membrane at term,” Placenta, 18:441-446 (1997). [cited by applicant]
Parolini et al., “Concise review: isolation and characterization of cells from human term placenta: outcome of the first international workshop on placenta derived stem cells,” Stern Cells, 26(2):300-311 (2008). [cited by applicant]
Pascher et al., “Biologies in the treatment of transplant rejection and ischemia/reperfusion injury,” BioDrugs, 19 (4):211-231 (2005). [cited by applicant]
Pastar et al., “Role of keratinocytes in healing of chronic wounds,” Surg. Technol. Int., 17:105-12 (2008). [cited by applicant]
Portmann-Lanz et al., “Isolation and characterization of mesenchymal cells from human fetal membranes,” J. Tissue Eng. Regen. Med., 1(4):296-305 (2007). [cited by applicant]
Portmann-Lanz et al., “Placental mesenchymal stem cells as potential autologous graft for pre- and perinatal neuroregeneration,” Am. J. Obstet. Gynecol., 194:664-673 (2006). [cited by applicant]
Presta et al., “Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis,” Cytokine & Growth Factor Reviews, 16:159-178 (2005). [cited by applicant]
Rama, P. et al., Further Evaluation of Amniotic Membrane Banking for Transplantation in Ocular Surface Diseases. Cell Tissue Bank. 2001; 2(3) :155-63. [cited by applicant]
Ramakrishnan, K.M. and V. Jayaraman, Management of partialthickness burn wounds by amniotic membrane: a cost-effective treatment in developing countries. Burns, 1997. 23 Suppl 1: p. 833-6. [cited by applicant]
Rao, T.V. and V. Chandrasekharam, Use of dry human and bovine amnion as a biological dressing. Arch Surg, 1981. 116(7): p. 891-6. [cited by applicant]
Ravishanker, R., A.S. Bath, and R. Roy, “Amnion Bank”—the use of long term glycerol preserved amniotic membranes in the management of superficial and superficial partial thickness burns. Burns, 2003. 29(4): p. 369-74. [cited by applicant]
Reuss et al., “Fibroblast growth factors and their receptors in the central nervous system,” Cell Tissue Res., 313:139-157 (2003). [cited by applicant]
Saksela, et al., “Presence of α2Macroglobulin in Normal but Not in Malignant Human Syncytiotrophoblasts” Dept. of Virology, Cancer Res. 41, 2507-2513, Jun. 1981. [cited by applicant]
Sangwan et al., “Treatment of uveitis: beyond steroids,” Indian J. Ophthalmol., 58(1):1-2 (2009). [cited by applicant]
Sawhney, C.P., Amniotic membrane as a biological dressing in the management of bums. Bums, 1989. 15(5): p. 339-42. [cited by applicant]
Sekine et al., “Role of passenger leukocytes in allograft rejection: effect of depletion of donor alveolar macrophages on the local production of TNF-alpha, T helper 1/T helper 2 cytokines, IgG subclasses, and pathology… [cited by applicant]
Sen et al. “Oxygen, Oxidants, and Antioxidants in Wound Healing An Emerging Paradigm” Ann. 1-79 N.Y. Acad. Sci. May 1, 2002 (May 1, 2002), vol. 957, PQs. 239-249. [cited by applicant]
Shalaby et al., “The involvement of human tumor necrosis factors-alpha and -beta in the mixed lymphocyte reaction,” J. Immunol., 141:499-503 (1988). [cited by applicant]
Shapiro, “Bone development and tis relation to fracture repair. The role of mesenchymal osteoblasts and surface osteoblasts,” Eur. Cell. Mat., 15:53-76 (2008). [cited by applicant]
Shen et al., “IL-6 and TNF-Synergistically Inhibit Allograf! Acceptance,” J. Am. Soc. Nephrol., 20:1032-1040 (2009). [cited by applicant]
Shimmura et al., “Antiinflammatory effects of amniotic membrane transplantation in ocular surface disorders,” Cornea, 20{4 ):408-413 (2001). [cited by applicant]
Singh, R., et al., Microbiological safety and clinical efficacy of radiation sterilized amniotic membranes for treatment of second-degree bums. Burns, 2007. 33(4): p. 505-10. [cited by applicant]
“Sonicini, M. et al., ““Isolation and characterization of mesenchymal cells from human fetal membranes””, Journal of Tissue Engineering and Regenerative Medicine, 1, pp. 296-305, Jun. 13, 2007 (Jun. 13, 2007)”. [cited by applicant]
Splichal, 1. and 1. Trebichavsky, Cytokines and other important inflammatory mediators in gestation and bacterial intraamniotic infections. Folia Microbiol (Praha). 2001. 46(4): p. 345-51. [cited by applicant]
Su et al., “Molecular profile of endothelial invasion of three-dimensional collagen matrices: insights into angiogenic sprout induction in wound healing,” Am. J. Physiol. Cell Physiol., 295:C1215-C1229 (2008). [cited by applicant]
Subbota et al., Abstracts 1 Cryobiology. 2006; 53:415. [cited by applicant]
Tadmori et al., “Suppression of the allogeneic response by human IL-10: a critical role for suppression of a synergy between IL-2 and TNF-alpha,” Cytokine, 6:462-471 (1994). [cited by applicant]
Taylor et al., “Function of Lymphocytes and Macrophages after Cryopreservation by Procedures for Pancreatic Islets: Potential for Reducing Tissue Immunogenicity,” Cryobiology, 25:1-17 (1988). [cited by applicant]
Taylor, Pamela V; Hancock KW; “Antigenicity of Trophoblast and Possible Antigen-masking Effects during Pregnancy” Immunology, 28, 973-982, (1975). [cited by applicant]
Thiex et al., “Tissue-specific cytokine release from human extra-placental membranes stimulated by lipopolysaccharide in a two-compartment tissue culture system,” Reprod. Biol. Endocrinol., 7:117 (2009). [cited by applicant]
Thivolet et al., “Long-term survival and immunological tolerance of human epidermal allografts produced in culture,” Transplantation, 42:274-280 (1986). [cited by applicant]
Thomasen, H. et al., Comparison of Cryopreserved and Air-dried Human Amniotic Membrane for Opthalmologic Applications. Graefes Arch Clin Exp Opthalmol. 2009; 24 7(12):1691-700. [cited by applicant]
Toungouz et al., “Alloactivation induced during mixed-lymphocyte reaction provokes release of tumor necrosis factor alpha and interleukin 6 by macrophages and primes them to lipopolysaccharides,” Hum. Immunol., 38:221-2… [cited by applicant]
Tredget et al., “Hypertrophic scars, keloids, and contractures. The cellular and molecular basis for therapy,” Surg. Clin. North Am., 77:701-730 (1997). [cited by applicant]
Tredget, E.E., et al., Transforming growth factor-beta in thermally injured patients with hypertrophic scars: effects of interferon alpha-2b. Plast Reconstr Surg, 1998. 102(5): p. 1317-28; discussion 1329-30. [cited by applicant]
Trengove et al., “Analysis of the acute and chronic wound environments: the role of proteases and their inhibitors,” Wound Repair Regen., 7:442-452 (1999). [cited by applicant]
Tseng et al. “Amniotic Membrane Transplantation With or Without Limbal Allografts for Corneal A Surface Reconstruction in Patients with Limbal Stern Cell Deficiency” Arch Ophthalmol. (1998); 116(4):431-41. [cited by applicant]
Ucakhan et al., “Nonpreserved human amniotic membrane transplantation in acute and chronic chemical eye injuries,” Cornea, 21 : 169-172 (2002). [cited by applicant]
Uchide et al. “Possible Role of Proinflammatory and Chemoattractive Cytokines Produced by Human Fetal Membrane Cells in the Pathology of Adverse Pregnancy Outcomes Associated with Influenza Virus Infection.” Hindawi Pub… [cited by applicant]
Uchino, Y,, et al: “Amniotic membrane immobilized poly(vinyl alcohol) hybrid polymer as an artificial cornea scaffold that supports a stratified and differentiated corneal epithelium”. Journal of Biomedical Materials Re… [cited by applicant]
Ugar, N. and M. Haberal, Comparison of various dressing materials used for out-patient bum treatment at our centre. Ann Med Burn Club, 1994. 7. [cited by applicant]
U.S. Non-Final Office Action issued in related U.S. Appl. No. 17/401,758, dated Dec. 8, 2022. [cited by applicant]
Vaalamo et al., “Differential expression of tissue inhibitors of metalloproteinases (TIMP-1, -2, -3, and -4) in normal and aberrant wound healing,” Hum. Pathol., 30:795-802 (1999). [cited by applicant]
Validation of Analytical Procedures: Text and Methodology Q2 (R1) (1994). [cited by applicant]
Waddington et al., “Differential roles for small leucine-rich proteoglycans in bone formation,” Eur. Gell. Mat., 6:12-21 (2003). [cited by applicant]
Wang et al., “Interleukin-10 Modulation of Alloreactivity and Graft-Versus-Host Reactions,” Transplantation, 74:772-778 (2002). [cited by applicant]
Wenstrup et al., “Type V Collagen Controls the Initiation of Collagen Fibril Assembly,” J. Biol. Chem., 279 (51 ):53331-53337 (2004). [cited by applicant]
Wingenfeld et al., “Cryopreservation of Osteochondral Allografts: Dimethyl Sulfoxide Promotes Angiogenesis and Immune Tolerance in Mice,” J. Bane Joint Surg. Am., 84-A:1420-1429 (2002). [cited by applicant]
Yu et al., “Bone morphogenetic protein 2 stimulates endochondral ossification by regulating periosteal cell fate during bone repair,” Bone, 47(1):65-73 (2010). [cited by applicant]
Zaga et al., “Secretions of Interleukin-1 band Tumor Necrosis Factor a by Whole Fetal Membranes Depend on Initial Interactions of Amnion or Choriodecidua with Lipopolysaccharides or Group B Streptococci,” Biol. Reprod.,… [cited by applicant]
Zaga-Clavellina et al., “In vitro secretion profiles of interleukin (IL)-1beta, IL-6, IL-8, IL-10, and TNF alpha after selective infection with [cited by applicant]
Zhang X et al: “Mesenchymal progenitor cells derived from chorionic villi of human placenta for cartilage tissue engineering”, Biochemical and Biophysical Research Communications, (2006) 340(3) :944-952. [cited by applicant]
McQuilling, JP et al., “Characteristics of dehydrated amnion chorion membranes and evaluation of fibroblast and keratinocytes responses in vitro”, [cited by applicant]
Office Action issued in corresponding U.S. Appl. No. 17/401,758, dated Nov. 9, 2023. [cited by applicant]
Office Action issued in corresponding U.S. Appl. No. 17/971,980, dated Nov. 22, 2023. [cited by applicant]
Office Action issued in corresponding U.S. Appl. No. 18/101,727, dated Jan. 24, 2024. [cited by applicant]
Xu et al., “Expression of Matrix Metalloproteinase (MMP)-2 and MMP-9 in Human Placenta and Fetal Membrane in Relation to Preterm and Term Labor,” The Journal of Clinical Endocrinology and Metabolism, 2002, vol. 87, No. … [cited by applicant]
Weiss et al. “The matrix metalloproteinases (MMPS) in the decidua and fetal membranes”, [cited by applicant]